Penumbra, Inc (PEN) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 3.95%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 3.95% | Share-based compensation / revenue. Period ending 2026-06-30. $59.50M ÷ $1.50B × 100 ≈ 3.95% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 1.50B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 59.50M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 187.34M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.50B | $59.50M | $187.34M | (m) | (m) | 3.95% | (m) | (m) |
| 2026-03-31 | (m) | $1.45B | $60.07M | $187.13M | (m) | (m) | 4.13% | (m) | (m) |
| 2025-12-31 | (m) | $1.40B | $59.21M | $189.25M | (m) | (m) | 4.22% | (m) | (m) |
| 2025-09-30 | (m) | $1.33B | $56.05M | $172.79M | (m) | (m) | 4.20% | (m) | (m) |
| 2025-06-30 | (m) | $1.28B | $51.05M | $159.32M | (m) | (m) | 3.99% | (m) | (m) |
| 2025-03-31 | (m) | $1.24B | $46.38M | $37.53M | (m) | (m) | 3.74% | (m) | (m) |
| 2024-12-31 | (m) | $1.19B | $46.16M | $9.28M | (m) | (m) | 3.86% | (m) | (m) |
| 2024-09-30 | (m) | $1.16B | $44.86M | $1.53M | (m) | (m) | 3.85% | (m) | (m) |
| 2024-06-30 | (m) | $1.13B | $48.06M | $-21.21M | $1.63M | (m) | 4.24% | -13.05× | Reported |
| 2024-03-31 | (m) | $1.10B | $51.32M | $77.64M | $1.73M | (m) | 4.68% | 45.01× | Reported |
| 2023-12-31 | (m) | $1.06B | $50.52M | $73.55M | $1.74M | (m) | 4.77% | 42.29× | Reported |
| 2023-09-30 | (m) | $995.06M | $49.72M | $43.35M | (m) | (m) | 5.00% | (m) | (m) |
| 2023-06-30 | (m) | $937.79M | $45.29M | $36.16M | (m) | (m) | 4.83% | (m) | (m) |
| 2023-03-31 | (m) | $884.64M | $41.25M | $18.14M | (m) | (m) | 4.66% | (m) | (m) |
| 2022-12-31 | (m) | $847.13M | $37.38M | $6.08M | (m) | (m) | 4.41% | (m) | (m) |
| 2022-09-30 | (m) | $829.93M | $69.04M | $-38.81M | (m) | (m) | 8.32% | (m) | (m) |
| 2022-06-30 | (m) | $806.37M | $67.24M | $-35.46M | (m) | (m) | 8.34% | (m) | (m) |
| 2022-03-31 | (m) | $782.28M | $68.26M | $-25.01M | (m) | (m) | 8.73% | (m) | (m) |
| 2021-12-31 | (m) | $747.59M | $65.76M | $-7.50M | (m) | (m) | 8.80% | (m) | (m) |
| 2021-09-30 | (m) | $710.48M | $32.16M | $30.81M | (m) | (m) | 4.53% | (m) | (m) |
| 2021-06-30 | (m) | $671.44M | $30.49M | $1.87M | (m) | (m) | 4.54% | (m) | (m) |
| 2021-03-31 | (m) | $592.29M | $26.25M | $-26.09M | (m) | (m) | 4.43% | (m) | (m) |
| 2020-12-31 | (m) | $560.41M | $25.54M | $-38.94M | (m) | (m) | 4.56% | (m) | (m) |
| 2020-09-30 | (m) | $538.78M | $22.50M | $-26.62M | (m) | (m) | 4.18% | (m) | (m) |
| 2020-06-30 | (m) | $527.20M | $22.50M | $6.52M | (m) | (m) | 4.27% | (m) | (m) |
| 2020-03-31 | (m) | $556.29M | $22.08M | $36.97M | (m) | (m) | 3.97% | (m) | (m) |
| 2019-12-31 | (m) | $547.40M | $21.48M | $47.51M | (m) | (m) | 3.92% | (m) | (m) |
| 2019-09-30 | $49.73M | $522.93M | $21.34M | $43.60M | (m) | 9.51% | 4.08% | (m) | (m) |
| 2019-06-30 | $45.09M | $495.24M | $19.51M | $9.77M | (m) | 9.10% | 3.94% | (m) | (m) |
| 2019-03-31 | $39.82M | $470.68M | $19.36M | $6.25M | (m) | 8.46% | 4.11% | (m) | (m) |
| 2018-12-31 | $36.16M | $444.94M | $18.42M | $-852.00K | (m) | 8.13% | 4.14% | (m) | (m) |
| 2018-09-30 | (m) | $420.20M | $18.27M | $-3.67M | (m) | (m) | 4.35% | (m) | (m) |
| 2018-06-30 | $32.74M | $392.30M | $18.35M | $17.87M | (m) | 8.35% | 4.68% | (m) | (m) |
| 2018-03-31 | $32.64M | $363.25M | $17.95M | $7.26M | (m) | 8.99% | 4.94% | (m) | (m) |
| 2017-12-31 | $31.66M | $333.76M | $17.81M | $1.17M | (m) | 9.49% | 5.34% | (m) | (m) |
| 2017-09-30 | $29.37M | $310.82M | $16.93M | $-3.84M | (m) | 9.45% | 5.45% | (m) | (m) |
| 2017-06-30 | $27.74M | $294.09M | $16.70M | $-5.89M | (m) | 9.43% | 5.68% | (m) | (m) |
| 2017-03-31 | $25.91M | $278.61M | $15.63M | $-5.23M | (m) | 9.30% | 5.61% | (m) | (m) |
| 2016-12-31 | $23.88M | $263.32M | $14.64M | $-1.35M | (m) | 9.07% | 5.56% | (m) | (m) |
| 2016-09-30 | $23.25M | $244.63M | $12.95M | $1.62M | (m) | 9.50% | 5.29% | (m) | (m) |
| 2016-06-30 | $21.31M | $227.86M | $10.19M | $5.17M | (m) | 9.35% | 4.47% | (m) | (m) |
| 2016-03-31 | $19.84M | $205.06M | $9.93M | $2.02M | (m) | 9.67% | 4.84% | (m) | (m) |
| 2015-12-31 | $18.03M | $186.09M | $7.27M | $4.18M | (m) | 9.69% | 3.91% | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $149.13M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $138.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $15.57M | $125.51M | $1.43M | $3.01M | (m) | 12.41% | 1.14% | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $14.08M | $88.85M | $886.00K | $-1.13M | (m) | 15.85% | 1.00% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| Heartflow, Inc. (HTFL) | United States | $4.225B |